Heat shock protein 90 as a molecular target for cancer therapeutics
Top Cited Papers
Open Access
- 1 March 2003
- journal article
- review article
- Published by Elsevier in Cancer Cell
- Vol. 3 (3), 213-217
- https://doi.org/10.1016/s1535-6108(03)00029-1
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- BCR-ABL point mutants isolated from patients with imatinib mesylate–resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90Blood, 2002
- The Assembly and Intermolecular Properties of the hsp70-Hop-hsp90 Molecular Chaperone ComplexJournal of Biological Chemistry, 2002
- Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1α-degradative PathwayJournal of Biological Chemistry, 2002
- Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau proteinCancer Cell, 2002
- Stimulation of the weak ATPase activity of human Hsp90 by a client protein 1 1Edited by G. von HeijneJournal of Molecular Biology, 2002
- HSP90 as a new therapeutic target for cancer therapy: the story unfoldsExpert Opinion on Biological Therapy, 2002
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002
- Sensitivity of Mature ErbB2 to Geldanamycin Is Conferred by Its Kinase Domain and Is Mediated by the Chaperone Protein Hsp90Journal of Biological Chemistry, 2001
- Mutations of the VHL tumour suppressor gene in renal carcinomaNature Genetics, 1994
- Von Hippel–Lindau disease maps to the region of chromosome 3 associated with renal cell carcinomaNature, 1988